OBSV - ObsEva SA

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.41
-0.92 (-5.63%)
At close: 4:00PM EDT

15.00 -0.41 (-2.66%)
Pre-Market: 5:58AM EDT

Stock chart is not supported by your current browser
Previous Close16.33
Open16.25
Bid15.00 x 800
Ask16.00 x 1000
Day's Range14.85 - 16.45
52 Week Range6.15 - 20.35
Volume263,491
Avg. Volume130,985
Market Cap699.326M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.21
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.25
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    ObsEva SA to start trading today on the SIX Swiss Exchange

    July 13, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced that its shares will be listed and start trading today under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45`381`252 registered shares with a nominal value of 1/13 of CHF 1 each.

  • GlobeNewswire4 days ago

    ObsEva SA to start trading today on the SIX Swiss Exchange

    July 13, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced that its shares will be listed and start trading today under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45'381'252 registered shares with a nominal value of 1/13 of CHF 1 each.

  • Reuters11 days ago

    ObsEva plans Swiss listing; trading debut on July 13

    ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors. Geneva-based ObsEva, founded by gynaecologist and former Serono drug developer Ernest Loumaye, started trading on the Nasdaq in 2017 and has a market capitalisation of about $658 million. ObsEva, which will trade under the ticker symbol "OBSN.S", will not issue any new shares in connection with the Swiss listing.

  • GlobeNewswire11 days ago

    ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

    ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women. Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus.

  • GlobeNewswire11 days ago

    ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

    ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women. Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus.

  • GlobeNewswire27 days ago

    ObsEva Announces Pricing of Follow-on Public Offering

    June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters' option to purchase additional shares.  ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.

  • GlobeNewswire27 days ago

    ObsEva Announces Pricing of Follow-on Public Offering

    June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters` option to purchase additional shares.  ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.

  • GlobeNewswire29 days ago

    ObsEva Announces Launch of Proposed Follow-on Public Offering

    June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.

  • GlobeNewswire29 days ago

    ObsEva Announces Launch of Proposed Follow-on Public Offering

    June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.

  • GlobeNewswire29 days ago

    ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

    Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being High dose (200mg) of linzagolix achieves ...

  • GlobeNewswire29 days ago

    ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

    Partial suppression of estradiol with moderate dose of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being. High dose of linzagolix achieves full estradiol ...

  • GlobeNewswirelast month

    ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

    Geneva, Switzerland and Boston, MA - June 15, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...

  • GlobeNewswirelast month

    ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

    Geneva, Switzerland and Boston, MA- June 15, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...

  • GlobeNewswire2 months ago

    ObsEva SA to Seek SIX Share Listing

    Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX's international reporting standard. "Last years listing on the NY based NASDAQ was a major step for the company as it provides access to capital to pursue the development of our rich, late-stage clinical, product portfolio, hence moving closer to address the needs of millions of women worldwide and continue to create value for our shareholders" said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "Today as a Swiss company, we are proud and thrilled to announce our intention to be listed on SIX.

  • GlobeNewswire2 months ago

    ObsEva SA to Seek SIX Share Listing

    Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX`s international reporting standard. "Last years listing on the NY based NASDAQ was a major step for the company as it provides access to capital to pursue the development of our rich, late-stage clinical, product portfolio, hence moving closer to address the needs of millions of women worldwide and continue to create value for our shareholders" said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "Today as a Swiss company, we are proud and thrilled to announce our intention to be listed on SIX.

  • GlobeNewswire2 months ago

    ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018

    Geneva, Switzerland and Boston, MA -May 31, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...

  • GlobeNewswire2 months ago

    ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018

    Geneva, Switzerland and Boston, MA- May 31, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of OBSV.O earnings conference call or presentation 16-May-18 12:00pm GMT

    Q1 2018 Obseva SA Earnings Call

  • ObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    ObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call Transcript

    OBSV earnings call for the period ending March 31, 2018.

  • With A -121.60% Earnings Drop, Did ObsEva SA (NASDAQ:OBSV) Really Underperform?
    Simply Wall St.2 months ago

    With A -121.60% Earnings Drop, Did ObsEva SA (NASDAQ:OBSV) Really Underperform?

    After looking at ObsEva SA’s (NASDAQ:OBSV) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • GlobeNewswire2 months ago

    ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

    -Key First Quarter 2018 Clinical Milestones Achieved. Patient randomization completed in Phase 2 b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2: 18, and Primary endpoint ...

  • GlobeNewswire2 months ago

    ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

    -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2:18, and   Primary endpoint ...

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Care, Unilever, CECO Environmental, Carter's, ObsEva SA, and ViewRay — Fundamental Analysis, Key Performance Indications

    NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Care.com, ...

  • GlobeNewswire2 months ago

    ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018

    Geneva, Switzerland and Boston, MA- May 8, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...

  • GlobeNewswire2 months ago

    ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018

    Geneva, Switzerland and Boston, MA - May 8, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...